 Amrut Ambardekar
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 36 | 2023 | 485 | 9.070 |
Why?
| | Heart Failure | 50 | 2023 | 1969 | 6.970 |
Why?
| | Heart Transplantation | 23 | 2023 | 671 | 5.460 |
Why?
| | Amyloidosis | 4 | 2023 | 40 | 2.000 |
Why?
| | Heart Ventricles | 9 | 2020 | 727 | 1.750 |
Why?
| | Cardiomyopathies | 7 | 2023 | 299 | 1.560 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 344 | 1.240 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 374 | 1.140 |
Why?
| | Myocardium | 10 | 2023 | 970 | 1.020 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 277 | 0.970 |
Why?
| | Myocytes, Cardiac | 11 | 2023 | 472 | 0.920 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 228 | 0.920 |
Why?
| | Humans | 97 | 2023 | 118972 | 0.890 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 299 | 0.880 |
Why?
| | Rejuvenation | 1 | 2022 | 14 | 0.870 |
Why?
| | Assisted Circulation | 2 | 2021 | 24 | 0.850 |
Why?
| | Echocardiography | 7 | 2017 | 556 | 0.840 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 42 | 0.830 |
Why?
| | Transplant Recipients | 4 | 2021 | 148 | 0.830 |
Why?
| | Fibrosis | 5 | 2022 | 483 | 0.830 |
Why?
| | Hemodynamics | 7 | 2023 | 1003 | 0.820 |
Why?
| | Vascular Stiffness | 2 | 2017 | 425 | 0.790 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 681 | 0.780 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 61 | 0.770 |
Why?
| | Giant Cells | 1 | 2020 | 22 | 0.770 |
Why?
| | Stroke Volume | 8 | 2023 | 512 | 0.760 |
Why?
| | Arteries | 1 | 2022 | 250 | 0.750 |
Why?
| | Aortic Diseases | 1 | 2021 | 94 | 0.750 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 468 | 0.740 |
Why?
| | Heart Neoplasms | 1 | 2020 | 50 | 0.740 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 73 | 0.720 |
Why?
| | Myocarditis | 1 | 2020 | 95 | 0.700 |
Why?
| | Coronary Vessels | 2 | 2018 | 233 | 0.700 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 257 | 0.700 |
Why?
| | Middle Aged | 33 | 2022 | 27617 | 0.680 |
Why?
| | Graft Rejection | 3 | 2021 | 555 | 0.660 |
Why?
| | Brugada Syndrome | 2 | 2009 | 10 | 0.660 |
Why?
| | Myocardial Contraction | 4 | 2020 | 339 | 0.650 |
Why?
| | Bariatric Surgery | 1 | 2021 | 166 | 0.650 |
Why?
| | Heart | 6 | 2023 | 631 | 0.630 |
Why?
| | Extracellular Matrix | 1 | 2021 | 446 | 0.630 |
Why?
| | Male | 45 | 2022 | 57801 | 0.610 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 229 | 0.590 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 251 | 0.580 |
Why?
| | Female | 45 | 2022 | 61564 | 0.560 |
Why?
| | Thrombosis | 2 | 2016 | 309 | 0.540 |
Why?
| | Cryosurgery | 1 | 2016 | 54 | 0.530 |
Why?
| | Heart Rate | 2 | 2021 | 729 | 0.530 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 215 | 0.500 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 151 | 0.490 |
Why?
| | Blood Pressure | 5 | 2022 | 1664 | 0.480 |
Why?
| | Marijuana Abuse | 1 | 2016 | 209 | 0.470 |
Why?
| | Electrocardiography | 4 | 2020 | 556 | 0.470 |
Why?
| | Aged | 19 | 2022 | 19657 | 0.460 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 248 | 0.440 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 490 | 0.440 |
Why?
| | Treatment Outcome | 12 | 2021 | 9342 | 0.440 |
Why?
| | Myofibrils | 3 | 2022 | 50 | 0.440 |
Why?
| | Patient-Centered Care | 2 | 2021 | 497 | 0.420 |
Why?
| | Adult | 21 | 2023 | 31512 | 0.420 |
Why?
| | Guideline Adherence | 3 | 2011 | 523 | 0.400 |
Why?
| | Patient Compliance | 2 | 2017 | 537 | 0.380 |
Why?
| | Cardiology | 2 | 2023 | 272 | 0.380 |
Why?
| | Recovery of Function | 2 | 2011 | 604 | 0.370 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 16 | 0.370 |
Why?
| | Hospitals, Rural | 1 | 2009 | 29 | 0.360 |
Why?
| | Risk Assessment | 6 | 2021 | 3057 | 0.360 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 161 | 0.360 |
Why?
| | Cannabis | 1 | 2016 | 382 | 0.360 |
Why?
| | Calcium | 4 | 2023 | 1169 | 0.360 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2174 | 0.350 |
Why?
| | Sarcomeres | 3 | 2022 | 91 | 0.350 |
Why?
| | Baroreflex | 2 | 2021 | 53 | 0.350 |
Why?
| | Cardiac Output | 3 | 2023 | 147 | 0.350 |
Why?
| | Automobile Driving | 1 | 2011 | 128 | 0.350 |
Why?
| | Safety | 1 | 2011 | 304 | 0.350 |
Why?
| | Hospitals, Urban | 1 | 2009 | 129 | 0.340 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 74 | 0.340 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 85 | 0.340 |
Why?
| | Registries | 6 | 2021 | 1810 | 0.340 |
Why?
| | Pulsatile Flow | 2 | 2018 | 54 | 0.330 |
Why?
| | Vascular Remodeling | 2 | 2021 | 152 | 0.320 |
Why?
| | Counseling | 1 | 2011 | 353 | 0.320 |
Why?
| | Mastitis | 1 | 2007 | 4 | 0.320 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 46 | 0.320 |
Why?
| | Length of Stay | 2 | 2009 | 1032 | 0.320 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1384 | 0.310 |
Why?
| | Puerperal Disorders | 1 | 2007 | 33 | 0.310 |
Why?
| | Prospective Studies | 10 | 2021 | 6471 | 0.300 |
Why?
| | Coronary Disease | 1 | 2009 | 356 | 0.300 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 325 | 0.300 |
Why?
| | Retrospective Studies | 13 | 2023 | 12978 | 0.290 |
Why?
| | Environment | 1 | 2009 | 346 | 0.290 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4596 | 0.280 |
Why?
| | HIV Infections | 1 | 2020 | 2459 | 0.280 |
Why?
| | Diastole | 2 | 2018 | 145 | 0.280 |
Why?
| | Inpatients | 1 | 2009 | 388 | 0.270 |
Why?
| | Troponin I | 2 | 2019 | 83 | 0.260 |
Why?
| | Quality of Health Care | 1 | 2009 | 586 | 0.250 |
Why?
| | Perioperative Care | 2 | 2017 | 132 | 0.240 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.230 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 34 | 0.230 |
Why?
| | Patient Transfer | 2 | 2019 | 143 | 0.230 |
Why?
| | Preoperative Care | 2 | 2017 | 332 | 0.220 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 31 | 0.220 |
Why?
| | Quality of Life | 5 | 2023 | 2366 | 0.220 |
Why?
| | Heart Injuries | 1 | 2023 | 38 | 0.220 |
Why?
| | MicroRNAs | 2 | 2022 | 637 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2062 | 0.220 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 84 | 0.220 |
Why?
| | Metalloproteases | 1 | 2022 | 38 | 0.220 |
Why?
| | Cohort Studies | 6 | 2023 | 5116 | 0.210 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 409 | 0.210 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 13 | 0.210 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 10 | 0.210 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 10 | 0.210 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 15 | 0.210 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 99 | 0.210 |
Why?
| | Succinic Acid | 2 | 2019 | 46 | 0.210 |
Why?
| | Leukopenia | 1 | 2021 | 27 | 0.200 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.200 |
Why?
| | Cardiovascular System | 1 | 2023 | 127 | 0.200 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 217 | 0.200 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 20 | 0.200 |
Why?
| | Pressoreceptors | 1 | 2021 | 18 | 0.190 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 79 | 0.190 |
Why?
| | Case-Control Studies | 4 | 2022 | 3171 | 0.190 |
Why?
| | Alternative Splicing | 1 | 2022 | 193 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2022 | 726 | 0.190 |
Why?
| | Hospitalization | 3 | 2022 | 1785 | 0.190 |
Why?
| | Muscle Proteins | 1 | 2022 | 219 | 0.190 |
Why?
| | Hypertension | 2 | 2020 | 1203 | 0.190 |
Why?
| | Myocardial Infarction | 2 | 2023 | 968 | 0.190 |
Why?
| | Cell Adhesion | 2 | 2018 | 443 | 0.180 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2021 | 119 | 0.180 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1691 | 0.180 |
Why?
| | Disease Progression | 2 | 2018 | 2490 | 0.180 |
Why?
| | Consensus | 4 | 2023 | 534 | 0.180 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 105 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2020 | 211 | 0.170 |
Why?
| | United States | 9 | 2023 | 12555 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 246 | 0.170 |
Why?
| | HIV | 1 | 2020 | 210 | 0.170 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2674 | 0.170 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2513 | 0.170 |
Why?
| | Exercise Test | 4 | 2023 | 551 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 185 | 0.170 |
Why?
| | Mice | 11 | 2023 | 15520 | 0.170 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 278 | 0.160 |
Why?
| | Prognosis | 4 | 2021 | 3443 | 0.160 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 356 | 0.160 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 219 | 0.160 |
Why?
| | Filamins | 1 | 2018 | 16 | 0.160 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 189 | 0.160 |
Why?
| | Aortic Valve | 1 | 2022 | 401 | 0.160 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 226 | 0.160 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 190 | 0.160 |
Why?
| | Recurrence | 1 | 2020 | 975 | 0.150 |
Why?
| | Pilot Projects | 3 | 2019 | 1419 | 0.150 |
Why?
| | Mutation | 2 | 2018 | 3457 | 0.150 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 11 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 756 | 0.150 |
Why?
| | Anesthetics | 1 | 2017 | 58 | 0.150 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 204 | 0.150 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 143 | 0.150 |
Why?
| | Transition to Adult Care | 1 | 2017 | 58 | 0.150 |
Why?
| | Immunity, Cellular | 1 | 2018 | 270 | 0.150 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 17 | 0.150 |
Why?
| | Brain | 2 | 2018 | 2490 | 0.150 |
Why?
| | ErbB Receptors | 1 | 2020 | 569 | 0.140 |
Why?
| | Animals | 14 | 2023 | 33381 | 0.140 |
Why?
| | Self Care | 1 | 2019 | 357 | 0.140 |
Why?
| | Polypharmacy | 1 | 2017 | 75 | 0.140 |
Why?
| | Prosthesis Design | 3 | 2014 | 285 | 0.140 |
Why?
| | Down-Regulation | 2 | 2016 | 627 | 0.140 |
Why?
| | Histone Deacetylases | 1 | 2018 | 198 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2021 | 1753 | 0.140 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 236 | 0.140 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 60 | 0.140 |
Why?
| | Eligibility Determination | 1 | 2016 | 55 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 455 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 969 | 0.140 |
Why?
| | Drug Interactions | 1 | 2017 | 352 | 0.140 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 67 | 0.140 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1032 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 394 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 654 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1597 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 53 | 0.130 |
Why?
| | Postoperative Care | 1 | 2017 | 237 | 0.130 |
Why?
| | Tacrolimus | 1 | 2016 | 151 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 298 | 0.130 |
Why?
| | Hospital Mortality | 2 | 2009 | 814 | 0.130 |
Why?
| | Phosphorylation | 3 | 2019 | 1633 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 3588 | 0.130 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1125 | 0.130 |
Why?
| | Viscosity | 1 | 2015 | 83 | 0.130 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 52 | 0.130 |
Why?
| | Prescription Drugs | 1 | 2016 | 113 | 0.130 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 126 | 0.120 |
Why?
| | Elastic Modulus | 1 | 2015 | 118 | 0.120 |
Why?
| | Health Status | 1 | 2019 | 726 | 0.120 |
Why?
| | Atherosclerosis | 1 | 2018 | 345 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 647 | 0.120 |
Why?
| | Rats | 5 | 2022 | 5392 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2017 | 482 | 0.120 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1323 | 0.120 |
Why?
| | Vaccination | 1 | 2022 | 1222 | 0.120 |
Why?
| | Hip Prosthesis | 1 | 2014 | 33 | 0.120 |
Why?
| | Systole | 1 | 2014 | 168 | 0.120 |
Why?
| | Attitude to Health | 1 | 2017 | 410 | 0.120 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 53 | 0.120 |
Why?
| | Incidence | 3 | 2019 | 2424 | 0.120 |
Why?
| | Quality Improvement | 1 | 2021 | 963 | 0.120 |
Why?
| | Patient Selection | 2 | 2017 | 676 | 0.120 |
Why?
| | Young Adult | 6 | 2019 | 10793 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2014 | 120 | 0.110 |
Why?
| | Time Factors | 4 | 2023 | 6412 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2020 | 847 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2014 | 219 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2016 | 220 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 699 | 0.110 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 23 | 0.100 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 992 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2016 | 597 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2874 | 0.100 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 8 | 0.100 |
Why?
| | Risk Factors | 4 | 2020 | 9000 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1079 | 0.100 |
Why?
| | Decision Making | 1 | 2017 | 809 | 0.100 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 76 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 842 | 0.090 |
Why?
| | Connectin | 2 | 2022 | 26 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2020 | 69 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 164 | 0.090 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 164 | 0.090 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 144 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2445 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1657 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1795 | 0.090 |
Why?
| | Anticoagulants | 1 | 2014 | 559 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1047 | 0.090 |
Why?
| | Pericardial Effusion | 1 | 2010 | 18 | 0.090 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 133 | 0.090 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 195 | 0.090 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.090 |
Why?
| | Comorbidity | 2 | 2020 | 1527 | 0.090 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 72 | 0.090 |
Why?
| | DNA | 1 | 2016 | 1388 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2022 | 3730 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1185 | 0.090 |
Why?
| | Cells, Cultured | 3 | 2022 | 4077 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 301 | 0.080 |
Why?
| | Europe | 2 | 2020 | 356 | 0.080 |
Why?
| | Ultrasonography | 1 | 2012 | 716 | 0.080 |
Why?
| | Coronary Circulation | 1 | 2008 | 121 | 0.080 |
Why?
| | Transcription Factors | 1 | 2016 | 1570 | 0.080 |
Why?
| | Syndrome | 1 | 2008 | 344 | 0.080 |
Why?
| | Body Temperature | 1 | 2007 | 215 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 327 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 541 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 693 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 265 | 0.070 |
Why?
| | Delivery of Health Care | 2 | 2023 | 867 | 0.070 |
Why?
| | Survivors | 1 | 2009 | 418 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2022 | 2680 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2275 | 0.070 |
Why?
| | Clinical Protocols | 2 | 2017 | 238 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1440 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 439 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 399 | 0.060 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 43 | 0.060 |
Why?
| | Troponin | 1 | 2023 | 47 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 4552 | 0.060 |
Why?
| | Cytokines | 1 | 2011 | 1900 | 0.060 |
Why?
| | Genotype | 2 | 2020 | 1882 | 0.060 |
Why?
| | Travel | 1 | 2023 | 116 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1200 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 19 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 91 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 100 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 154 | 0.050 |
Why?
| | Adolescent | 4 | 2019 | 18480 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 50 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 38 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 166 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2478 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4709 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 150 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 2326 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2022 | 4908 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 310 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 12 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 21 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2022 | 345 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 85 | 0.050 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 140 | 0.050 |
Why?
| | Graft Survival | 1 | 2023 | 504 | 0.050 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 12 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 54 | 0.050 |
Why?
| | Culture Media | 1 | 2021 | 163 | 0.050 |
Why?
| | Cardiomegaly | 1 | 2022 | 168 | 0.050 |
Why?
| | Chronic Disease | 2 | 2017 | 1636 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 114 | 0.050 |
Why?
| | Seizures | 1 | 2023 | 345 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2023 | 625 | 0.050 |
Why?
| | Prealbumin | 1 | 2020 | 23 | 0.050 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 135 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 250 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2021 | 144 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 439 | 0.050 |
Why?
| | Heart Function Tests | 1 | 2020 | 61 | 0.050 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 42 | 0.050 |
Why?
| | Norepinephrine | 1 | 2021 | 212 | 0.050 |
Why?
| | Acylation | 1 | 2019 | 28 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 576 | 0.050 |
Why?
| | Electric Countershock | 1 | 2020 | 110 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 404 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 66 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 177 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 845 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 95 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 204 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 1001 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 252 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 9 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 311 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 481 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 586 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 331 | 0.040 |
Why?
| | Fibroblasts | 1 | 2022 | 842 | 0.040 |
Why?
| | Zebrafish | 1 | 2022 | 434 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 407 | 0.040 |
Why?
| | Lysine | 1 | 2019 | 248 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 80 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4708 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 130 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 170 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 433 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2020 | 354 | 0.040 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 11 | 0.040 |
Why?
| | Alleles | 1 | 2020 | 832 | 0.040 |
Why?
| | Tissue Donors | 1 | 2019 | 336 | 0.040 |
Why?
| | Autoradiography | 1 | 2017 | 72 | 0.040 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.040 |
Why?
| | Atropine | 1 | 2016 | 32 | 0.040 |
Why?
| | Loperamide | 1 | 2016 | 10 | 0.040 |
Why?
| | Antidiarrheals | 1 | 2016 | 15 | 0.040 |
Why?
| | Papio | 1 | 2017 | 92 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 381 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 149 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2020 | 401 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 749 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2021 | 648 | 0.040 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 20 | 0.040 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 42 | 0.040 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 58 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 200 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 571 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3174 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 194 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 142 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 291 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 814 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 217 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 568 | 0.030 |
Why?
| | Actins | 1 | 2018 | 404 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 453 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 755 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1868 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 136 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2707 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1267 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 454 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2025 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 1052 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 557 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 48 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 420 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 876 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1012 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9491 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 699 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 139 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2016 | 282 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1715 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 230 | 0.030 |
Why?
| | Creatine | 1 | 2013 | 56 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1132 | 0.030 |
Why?
| | Alanine | 1 | 2013 | 102 | 0.030 |
Why?
| | Glutamine | 1 | 2013 | 88 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1541 | 0.030 |
Why?
| | Chromatin | 1 | 2016 | 441 | 0.030 |
Why?
| | Dyspnea | 1 | 2014 | 201 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 565 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2657 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 392 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 556 | 0.030 |
Why?
| | Fatigue | 1 | 2014 | 297 | 0.030 |
Why?
| | Phenotype | 1 | 2020 | 3003 | 0.030 |
Why?
| | Lactic Acid | 1 | 2013 | 282 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 907 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 796 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1781 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 286 | 0.020 |
Why?
| | Child | 2 | 2019 | 19129 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2995 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 953 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 387 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 683 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6561 | 0.020 |
Why?
| | Infant | 1 | 2015 | 8293 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 951 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 309 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|